---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-041832"
form_type: "8-K"
ticker: "GRCE"
cik: "0001444192"
company_name: "Grace Therapeutics, Inc."
filed_at: "2024-09-25T23:59:59+00:00"
generated_at: "2026-05-31T01:46:39.300107+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Acasti Pharma completes enrollment in pivotal Phase 3 STRIVE-ON trial of GTX-104 for aSAH

## Summary
- Patient enrollment completed for GTX-104 (injectable nimodipine) vs oral nimodipine in 100 patients across ~25 U.S. hospitals.
- Data readout from STRIVE-ON safety trial expected early calendar 2025; primary endpoint is comparative adverse events including hypotension.
- NDA submission to FDA on track for first half of 2025, consistent with timeline.
- CEO Prashant Kohli says milestone achieved ahead of original expectations; believes GTX-104 may transform aSAH standard of care.

## SEC filing metadata
- accession: 0001140361-24-041832
- form_type: 8-K
- ticker: GRCE
- cik: 0001444192
- company_name: Grace Therapeutics, Inc.
- filed_at: 2024-09-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1444192/000114036124041832/0001140361-24-041832-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1444192/000114036124041832/ef20036277_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-041832
- JSON: https://secwatch.observer/filing/0001140361-24-041832.json
- Plain text: https://secwatch.observer/filing/0001140361-24-041832.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.